Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Extension Study of 1 mg/kg Pegunigalsidase Alfa in Patients With Fabry Disease

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function